Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Tae Life Sciences To Develop Groundbreaking Therapy For Difficult-to-treat Cancers, Including Head, Neck And Gbm; Announces $40m Series A Funding

by vcaonline.com posted 7months ago 171 views
TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A FundingCompany Becomes First to License TAE Technologies' Accelerator-based Beam Technology for Clinical Investigation FOOTHILL RANCH, Calif., March 12, 2018-- TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today. TAE Life Sciences has exclusively licensed intellectual property from TAE Technologies, Inc., the world's largest and most advanced private fusion energy company.